Effects of Palatinose™ on Weight Management and Body Composition
The Effects of Palatinose™ on Weight Management and Body Composition in Overweight and Obese Individuals
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Oxford, United Kingdom, OX3 0BP
- Oxford Brookes University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is healthy at the time of pre-examination
- Subject has a BMI of 25 - 35 kg/m² and motivated to lose weight
- Subject is aged 18 - 60 years at the time of pre-examination
Exclusion Criteria:
- Person suffers from an acute or chronic disease
- Person has known dietary restrictions or allergies to Foods
- Intake of medications which interfere with body composition, appetite, satiety or food intake
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Sucrose
Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing sucrose
|
sucrose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
|
|
EXPERIMENTAL: Palatinose(TM)
Test products i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals containing isomaltulose (Palatinose™)
|
isomaltulose containing food products, i.e. low-fat yogurt drink, fruits drink and sweetener sachet for cereals, consumed within an energy-reduced diet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body Weight Change
Time Frame: 12 weeks
|
Body weight Change over a 12-week period
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Body fat percentage
Time Frame: 12 weeks
|
Body fat percentage measured using the BodPod
|
12 weeks
|
|
postprandial respiratory quotient (RQ)
Time Frame: 120 minutes postprandial
|
postprandial energy metabolism, i.e. respiratory quotient (RQ) and fat oxidation measured by indirect calorimetry
|
120 minutes postprandial
|
|
BMI
Time Frame: 12 weeks
|
Body mass index (kg/m2)
|
12 weeks
|
|
Waist circumference
Time Frame: 12 weeks
|
Waist circumference assessed using a measuring tape
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Beneo_OBU_101108Final
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.